Applied BioCode Advances Nucleic Acid Testing with New Feature

Exciting Advancements in Nucleic Acid Testing

Applied BioCode is thrilled to announce a groundbreaking enhancement to its BioCode® Gastrointestinal Pathogen Panel (GPP). This new feature introduces a nucleic acid extraction claim designed specifically for the ThermoFisher Scientific KingFisher™ Flex platform. This improvement significantly broadens the capabilities for clinical laboratories utilizing the BioCode® GPP and is expected to streamline laboratory workflows.

Enhancing Diagnostic Efficiency

This enhancement allows laboratories to seamlessly integrate the BioCode® GPP with the KingFisher™ Flex extraction platform. As a result, clinical facilities can increase their throughput for gastrointestinal testing significantly. The BioCode® GPP enables the detection of 17 commonly prevalent gastrointestinal pathogens, providing a comprehensive diagnostic solution. By optimizing workflows, this new claim is anticipated to enhance patient care and lead to quicker, more accurate diagnoses.

Commitment to Flexible Solutions

Dr. Winston Ho, CEO of Applied BioCode, stated, "Expanding our nucleic acid extraction options to include KingFisher™ Flex is a testament to our dedication to providing flexible and robust solutions in the molecular diagnostics landscape. We are aware of the growing demand for adaptable testing workflows that cater to the diverse needs of our clinical partners, ultimately benefiting patient outcomes."

Versatility in Pathogen Detection

The BioCode® GPP stands out as one of the most versatile panels available, now supporting multiple extraction platforms. This flexibility aligns perfectly with Applied BioCode’s mission to innovate and meet the evolving demands from healthcare providers. By doing so, the company empowers laboratories to utilize their existing test instruments more effectively, all while enhancing their diagnostic capabilities.

Unique Barcoded Technology

At the heart of this innovation lies the Barcoded Magnetic Bead (BMB) technology employed in the BioCode® GPP. This unique technology not only simplifies but also speeds up the process of high-throughput molecular diagnostics. It delivers an economical, precise, and comprehensive solution that clinical laboratories across the U.S. and other regions can utilize. By expanding nucleic acid extraction options, this development assists laboratories in enhancing their operational flexibility and overall diagnostic capabilities.

About Applied BioCode

Applied BioCode is an innovative IVD diagnostics company that specializes in designing, developing, and commercializing multiplex testing products. The firm has ingeniously combined digital barcodes with immuno- and molecular chemistry to grow its pioneering Barcoded Magnetic Bead (BMB) technology. These micro BMBs, which are approximately the size of a human hair, can be tagged with molecular probes or immunochemistry, allowing them to be swiftly scanned and identified, encompassing up to 4,096 barcodes accurately for various biological targets.

Applied BioCode holds FDA 510K clearances for both its 17-plex Respiratory Pathogen Panel (RPP) and the 17-plex Gastrointestinal Pathogen Panel (GPP) through the BioCode® MDx-3000 automated system. Moreover, the GPP and RPP are CE-Marked, conforming to European regulations.

The company has also gained Emergency Use Authorization (EUA) for several assays related to COVID-19 detection, affirming its strong position within the diagnostics space. Additionally, Applied BioCode has received RUO (Research Use Only) designation for its Fungal Panel and STI + Resistance Panel (RUO). Partnerships with various diagnostic companies span applications across infectious and autoimmune diseases, allergies, the gut microbiome, and veterinary sectors.

Frequently Asked Questions

What is the new enhancement announced by Applied BioCode?

The new enhancement introduces a nucleic acid extraction claim for the BioCode® Gastrointestinal Pathogen Panel, compatible with the KingFisher™ Flex platform.

How does this improve laboratory workflows?

This enhancement streamlines operations in clinical laboratories, increasing throughput and improving the diagnostic efficiency of detecting gastrointestinal pathogens.

What is the significance of Barcoded Magnetic Bead technology?

Barcoded Magnetic Bead technology simplifies and accelerates molecular diagnostics by allowing accurate scanning and identification of multiple barcoded biological targets.

What pathogens can the BioCode® GPP detect?

It can detect 17 different gastrointestinal pathogens, providing a comprehensive diagnostic solution for clinicians.

How does Applied BioCode support diagnostic laboratories?

Applied BioCode supports laboratories by providing innovative multiplex testing solutions that enhance diagnostic capabilities and improve patient outcomes.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.